TX-PLANVIEW
5.7.2022 15:05:08 CEST | Business Wire | Press release
Planview , a global leader in Portfolio Management and Work Management solutions, today announced it has completed its acquisition of Tasktop, initially announced on May 18 .
“Bringing Mik Kersten and the Tasktop team into Planview will help deliver new levels of excellence to companies and industries navigating through change,” said Razat Gaurav, CEO of Planview. “By merging Tasktop’s institutional expertise in scaling software with Planview’s focus on delivering enterprise-scale visibility, we’ve created a new industry powerhouse poised to help organizations connect the business of software delivery and conduct their business transformations with unprecedented confidence and efficiency.”
The combination of Planview and Tasktop means customers work with a single, comprehensive organization with cutting-edge expertise in capabilities ranging from Value Stream Management (VSM) to Strategic Portfolio Management and Enterprise Agile Planning, among others. At a time when organizations are navigating business transformations amid a turbulent macroeconomic landscape, having a single partner that provides intelligence and visibility into the progress of those transformations helps ensure success.
According to a May 2022 Forrester blog, The Market For VSM And SPM Takes A Big Step Forward , “We see the Planview + Tasktop combination having the potential to shake up the (Strategic Portfolio Management) SPM and VSM marketplace and force it to evolve at an even faster pace by putting pressure on existing leaders in agile planning and DevOps management solutions.”
“To succeed with digital transformation, organizations must expand beyond Agile teams to portfolio-level business agility,” said Dean Leffingwell, creator of SAFe® and cofounder, Scaled Agile, Inc. “We’re headed in the right direction. With so many enterprises now deploying SAFe, and the shift from project to product described in Mik Kersten’s book gaining mind share, this new way of working and thinking is finding its way into the CEO’s office. This new paradigm is helping leaders effectively connect the strategic portfolio level with software delivery, which introduces huge opportunities for the business. It is great to see our Scaled Agile partners Planview and Tasktop coming together to help enterprises maximize and accelerate those opportunities.”
The newly combined entity affirms Planview’s leading position globally with 4,500 enterprise customers worldwide, more than 1,300 employees, and a combined FY21 revenue of approximately $400 million. Planview will continue to invest in and support the Tasktop product lines as standalone solutions in the immediate term and will evaluate product direction long term based on customer and industry feedback. As part of the transaction, Tasktop cofounder and CEO, Mik Kersten, has joined Planview as Chief Technology Officer. You can read more about the Tasktop team’s go-forward focus in Mik’s blog .
Sumeru Equity Partners , Tasktop’s lead investor, along with minority investors Elsewhere Partners and Yaletown Partners, and Tasktop’s management will be rolling part of their equity in the new combined entity and will maintain minority interest in Planview alongside its majority shareholders, TPG and TA Associates. Golub Capital provided committed debt financing and Jefferies LLC acted as financial advisors to Planview. Ropes & Gray served as legal counsel to Planview. AGC Partners acted as financial advisors to Tasktop / Sumeru Equity Partners, and Kirkland & Ellis served as legal counsel.
About Planview
Planview has one mission: to build the future of connected work. Our solutions enable organizations to connect the business from ideas to impact, empowering companies to accelerate the achievement of what matters most. Planview’s full spectrum of Portfolio Management and Work Management solutions create an organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enables customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, with locations around the world, Planview has more than 1,300 employees supporting 4,500 customers and 2.6 million users worldwide. For more information, visit www.planview.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220704005348/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom